Alembic Pharma’s arm receives USFDA approval for Fenofibrate Tablets

12 Feb 2019 Evaluate

Alembic Pharmaceuticals’ wholly owned step down subsidiary -- Orit Laboratories LLC has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fenofibrate Tablets USP, 54 mg and 160 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tricor Tablets, 54 mg and 160 mg, of AbbVie Inc. (AbbVie)

Fenofibrate Tablets USP, 54 mg and 160 mg are indicated as an adjunct to diet to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidaemia and for treatment of adult patients with severe hypertriglyceridemia.

Fenofibrate Tablets USP, 54 mg and 160 mg have an estimated market size of $92 million for twelve months ending December 2018 according to IQVIA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

939.85 9.85 (1.06%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.00
Dr. Reddys Lab 5942.65
Cipla 1345.35
Zydus Lifesciences 925.95
Lupin 1547.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.